Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Olema Pharmaceuticals Inc (OLMA)

Olema Pharmaceuticals Inc (OLMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 550,391
  • Shares Outstanding, K 55,934
  • Annual Sales, $ 0 K
  • Annual Income, $ -96,660 K
  • 60-Month Beta 2.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.44
Trade OLMA with:

Options Overview Details

View History
  • Implied Volatility 134.18% ( +49.64%)
  • Historical Volatility 60.25%
  • IV Percentile 91%
  • IV Rank 63.51%
  • IV High 188.26% on 10/17/23
  • IV Low 40.04% on 06/08/23
  • Put/Call Vol Ratio 0.07
  • Today's Volume 29
  • Volume Avg (30-Day) 512
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 11,436
  • Open Int (30-Day) 3,304

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.56
  • Number of Estimates 4
  • High Estimate -0.50
  • Low Estimate -0.59
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.20 +3.53%
on 04/30/24
11.73 -18.76%
on 04/12/24
-1.41 (-12.89%)
since 04/10/24
3-Month
9.20 +3.53%
on 04/30/24
16.77 -43.19%
on 02/13/24
-6.06 (-38.87%)
since 02/09/24
52-Week
5.02 +89.84%
on 05/30/23
17.79 -46.43%
on 11/08/23
+2.89 (+43.52%)
since 05/10/23

Most Recent Stories

More News
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

/CNW/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further...

ONCY : 1.1600 (-6.45%)
CELC : 17.17 (-1.04%)
OLMA : 9.48 (-3.66%)
BIO : 280.04 (+0.98%)
AZN : 77.54 (-0.09%)
ONC.TO : 1.58 (-6.51%)
Biotech's Developments in Race Against Rising Cancer Rates Revealed

USA News Group – According to a “highly troubling” new study, the rising number of cancer cases in young people is being attributed to “accelerated aging.” Further alarm is being spread by the...

ONCY : 1.1600 (-6.45%)
ONC.TO : 1.58 (-6.51%)
CELC : 17.17 (-1.04%)
OLMA : 9.48 (-3.66%)
BIO : 280.04 (+0.98%)
AZN : 77.54 (-0.09%)
Stocks Fall as Bond Yields Climb on Strong US Economic News

The S&P 500 Index ($SPX ) (SPY ) this morning is down -1.06%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.51%. Stock indexes this...

$SPX : 5,214.09 (unch)
SPY : 520.18 (unch)
$DOWI : 39,408.72 (+0.05%)
DIA : 394.48 (+0.12%)
$IUXX : 18,123.34 (+0.05%)
QQQ : 441.41 (+0.09%)
^BTCUSD : 60,914.28 (-2.60%)
ZNM24 : 108-235 (-0.33%)
HUM : 337.02 (+0.70%)
CVS : 56.17 (+0.88%)
UNH : 510.11 (+0.61%)
CNC : 78.26 (+0.79%)
Stocks Retreat as Bond Yields Jump on Diminished Fed Rate Cut Prospects

The S&P 500 Index ($SPX ) (SPY ) this morning is down -1.02%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.47%. Stock indexes this...

$SPX : 5,214.09 (unch)
SPY : 520.18 (unch)
$DOWI : 39,408.72 (+0.05%)
DIA : 394.48 (+0.12%)
$IUXX : 18,123.34 (+0.05%)
QQQ : 441.41 (+0.09%)
ZNM24 : 108-235 (-0.33%)
HUM : 337.02 (+0.70%)
CVS : 56.17 (+0.88%)
UNH : 510.11 (+0.61%)
ELV : 541.70 (+0.58%)
CNC : 78.26 (+0.79%)
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer

USA News Group – More people are getting breast cancer this year. Around 300,000 women and 2,800 men will find out they have it. While 1 out of every 8 women will hear they have breast cancer sometime...

ONCY : 1.1600 (-6.45%)
ONC.TO : 1.58 (-6.51%)
PFE : 28.02 (-0.57%)
ARVN : 31.36 (-1.85%)
OLMA : 9.48 (-3.66%)
AZN : 77.54 (-0.09%)
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer

USA News Group – More people are getting breast cancer this year. Around 300,000 women and 2,800 men will find out they have it. While 1 out of every 8 women will hear they have breast cancer sometime...

AVRN : 0.0125 (-30.56%)
ONCY : 1.1600 (-6.45%)
ONC.TO : 1.58 (-6.51%)
PFE : 28.02 (-0.57%)
ARVN : 31.36 (-1.85%)
OLMA : 9.48 (-3.66%)
AZN : 77.54 (-0.09%)
Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Received Fast Track designation from U.S. FDA for OP-1250 for the treatment of ER+/HER2- metastatic breast cancerReported progress across OP-1250 clinical...

OLMA : 9.48 (-3.66%)
Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer

SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement...

OLMA : 9.48 (-3.66%)
Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference

SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage...

OLMA : 9.48 (-3.66%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage...

OLMA : 9.48 (-3.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California....

See More

Key Turning Points

3rd Resistance Point 12.63
2nd Resistance Point 12.01
1st Resistance Point 10.93
Last Price 9.48
1st Support Level 9.23
2nd Support Level 8.61
3rd Support Level 7.53

See More

52-Week High 17.79
Fibonacci 61.8% 12.91
Fibonacci 50% 11.41
Fibonacci 38.2% 9.90
Last Price 9.48
52-Week Low 5.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar